Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the dosing of the first participant in a global Phase 1/1b clinical trial evaluating the safety, tolerability, pharmacokinetics, and efficacy of ZL-1503, a potential first-in-class IL-13/IL-31R bispecific antibody for the treatment of atopic dermatitis (AD). ZL-1503, which was identified and advanced internally by Zai Lab's discovery team, targets both IL-13 and IL-31 pathways with an extend.

Business Wire • Dec 8, 2025

Zai Lab Announces Updates to China's National Reimbursement Drug List

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the following medicines and indications have been renewed in the 2025 National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA): VYVGART® (efgartigimod alfa injection) is renewed for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive; NUZYRA® (omadacycl.

Business Wire • Dec 7, 2025

Zai Lab Limited: Declining Despite Making Progress - I See Opportunity (Reiterate Buy)

ZLAB is continuing to grow revenues through its Chinese in-licensed strategy. Continuing growth of in-licensed programs is mixed, with imminent approvals in China but also termination of key studies. However, I think the market is pushing this further and further into "undervalued," given the narrowing losses and promise of their own pipeline projects.

Seeking Alpha • Nov 11, 2025

Zai Lab Limited (ZLAB) Q3 2025 Earnings Call Transcript

Zai Lab Limited ( ZLAB ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Christine Chiou - Senior VP & Head of Investor Relations Ying Du - Founder, Chairperson & CEO Rafael Amado - President and Head of Global Research & Development Joshua Smiley - President & COO Yajing Chen - Chief Financial Officer Conference Call Participants Jonathan Chang Anupam Rama - JPMorgan Chase & Co, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Ziyi Chen - Goldman Sachs Group, Inc., Research Division Yuxi Dong - Jefferies LLC, Research Division Presentation Operator Hello, ladies and gentlemen. Thank you for standing by, and welcome to Zai Lab's Third Quarter 2025 Financial Results Conference Call.

Seeking Alpha • Nov 7, 2025

Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2025, along with recent product highlights and corporate updates. “Zai Lab is entering the next phase of our growth, powered by the rapid advancement of our global pipeline and supported by a commercially profitable and scalable business in China,” said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. “With zoci moving into pivotal develop.

Business Wire • Nov 6, 2025

Zai Lab Announces Participation in Investor Conferences in November and December 2025

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conferences in November and December 2025: Jefferies Global Healthcare Conference in London Fireside Chat: Wednesday, November 19, 2025 at 8:30AM GMT Location: London Citi's 2025 Global Healthcare Conference Fireside Chat: Tuesday, December 2, 2025 at 1:00PM ET Location: Miami, Florida Live webcas.

Business Wire • Oct 31, 2025

Zai Lab Limited (ZLAB) Discusses Updated Monotherapy Phase I Data for Suzhou and Outlines Next Steps in Clinical Development Transcript

Zai Lab Limited (NASDAQ:ZLAB ) Discusses Updated Monotherapy Phase I Data for Suzhou and Outlines Next Steps in Clinical Development October 24, 2025 11:00 AM EDT Company Participants Rafael Amado - President and Head of Global Research & Development Joshua Smiley - President & COO Conference Call Participants Jonathan Chang - Leerink Partners LLC, Research Division Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Linhai Zhao - Goldman Sachs Group, Inc., Research Division Yuxi Dong - Jefferies LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Zai Lab 2025 Triple Meeting Investor Call.

Seeking Alpha • Oct 24, 2025

Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced updated data from the global Phase 1 clinical trial of zocilurtatug pelitecan (zoci), formerly known as ZL-1310, (NCT06179069) demonstrating robust and durable responses in heavily pre-treated patients with extensive-stage small cell lung cancer (ES-SCLC). This data will be presented as an oral presentation and was included as part of the press program at the AACR-NCI-EORTC International Con.

Business Wire • Oct 24, 2025

Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its third quarter 2025 financial results and provide recent corporate updates on November 6, 2025, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (9:00 p.m. HKT). Conference Call and Webcast Information The live webcast can be accessed by visiting the Company's website at http://ir.zailaborator.

Business Wire • Oct 15, 2025

Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that a late-breaking abstract (LBA) featuring new data from its global Phase 1 clinical trial (NCT06179069) evaluating zocilurtatug pelitecan (zoci), formerly known as ZL-1310, has been selected for an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 22-26, 2025, in Boston, Massachusetts. The presentation will.

Business Wire • Oct 13, 2025